# EDGAR Filing Document

**Accession Number:** 0001224962
**File Stem:** 0001193125-25-286168
**Filing Date:** 2025-11
**Character Count:** 14861
**Document Hash:** 23735885aab4d411670bdf80e194467a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-286168.hdr.sgml**: 20251118

**ACCESSION NUMBER**: 0001193125-25-286168

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20251118

**DATE AS OF CHANGE**: 20251118

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Lyra Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001327273
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-91508
- **FILM NUMBER:** 251494801

**BUSINESS ADDRESS:**
- **STREET 1:** 480 ARSENAL WAY
- **CITY:** WATERTOWN
- **STATE:** MA
- **ZIP:** 02472
- **BUSINESS PHONE:** 617-373-4600

**MAIL ADDRESS:**
- **STREET 1:** 480 ARSENAL WAY
- **CITY:** WATERTOWN
- **STATE:** MA
- **ZIP:** 02472

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** 480 Biomedical, Inc.
- **DATE OF NAME CHANGE:** 20120927

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Arsenal Vascular, Inc.
- **DATE OF NAME CHANGE:** 20110826

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Arsenal Medical, Inc.
- **DATE OF NAME CHANGE:** 20090414
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** PERCEPTIVE ADVISORS LLC
- **CENTRAL INDEX KEY:** 0001224962

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**BUSINESS ADDRESS:**
- **STREET 1:** 51 ASTOR PLACE, 10TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10003
- **BUSINESS PHONE:** 646-205-5300

**MAIL ADDRESS:**
- **STREET 1:** 51 ASTOR PLACE, 10TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10003

## Ex-99

<u>Schedule A</u>

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;Fund | &nbsp;&nbsp;Date | &nbsp;&nbsp;Transaction | &nbsp;&nbsp;Number of shares |
| &nbsp;&nbsp;Perceptive Life Sciences Master Fund, Ltd. | &nbsp;&nbsp;11/14/2025 | &nbsp;&nbsp;Sale | &nbsp;&nbsp;28242<br>&nbsp;&nbsp;$3.8942<sup>(</sup><sup>1</sup><sup>)</sup> |
| &nbsp;&nbsp;Perceptive LS (A), LLC | &nbsp;&nbsp;11/14/2025 | &nbsp;&nbsp;Sale | &nbsp;&nbsp;3173<br>&nbsp;&nbsp;$3.8942 <sup>(1)</sup> |
| &nbsp;&nbsp;Perceptive Life Sciences Master Fund, Ltd. | &nbsp;&nbsp;11/17/2025 | &nbsp;&nbsp;Sale | &nbsp;&nbsp;3021<br>&nbsp;&nbsp;$3.85<sup>(</sup><sup>2</sup><sup>)</sup> |
| &nbsp;&nbsp;Perceptive LS (A), LLC | &nbsp;&nbsp;11/17/2025 | &nbsp;&nbsp;Sale | &nbsp;&nbsp;339<br>&nbsp;&nbsp;$3.85<sup>(2)</sup> |
| &nbsp;&nbsp;Perceptive Life Sciences Master Fund, Ltd. | &nbsp;&nbsp;11/18/2025 | &nbsp;&nbsp;Sale | &nbsp;&nbsp;5222<br>&nbsp;&nbsp;$3.6689 <sup>(</sup><sup>3</sup><sup>)</sup> |
| &nbsp;&nbsp;Perceptive LS (A), LLC | &nbsp;&nbsp;11/18/2025 | &nbsp;&nbsp;Sale | &nbsp;&nbsp;587<br>&nbsp;&nbsp;$3.6689 <sup>(3)</sup> |

---

------

<sup>1</sup> The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.85 to $3.91 inclusive. The reporting persons undertake to provide the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within such range.

<sup>2</sup> The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.85 to $3.85 inclusive. The reporting persons undertake to provide the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within such range.

<sup>3</sup> The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.65 to $3.75 inclusive. The reporting persons undertake to provide the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within such range.

------

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 9)**

**Lyra Therapeutics, Inc.**

*(Name of Issuer)*

**Common Stock, $0.001 par value**

*(Title of Class of Securities)*

**55234L204**

*(CUSIP Number)*

**Alexander Rakitin**<br>51 Astor Place, 10th Floor<br>New York NY 10003<br>(646) 205-5345

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**11/14/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **55234L204** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Perceptive Advisors LLC** | Name of reporting person<br>**Perceptive Advisors LLC** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**98301.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**98301.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**98301.00** | Aggregate amount beneficially owned by each reporting person<br>**98301.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**5.5%** | Percent of class represented by amount in Row (11)<br>**5.5%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IA** | Type of Reporting Person (See Instructions)<br>**IA** | |

---

| **CUSIP No.** | **55234L204** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Joseph Edelman** | Name of reporting person<br>**Joseph Edelman** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**98301.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**98301.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**98301.00** | Aggregate amount beneficially owned by each reporting person<br>**98301.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**5.5%** | Percent of class represented by amount in Row (11)<br>**5.5%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

| **CUSIP No.** | **55234L204** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Perceptive Life Sciences Master Fund, Ltd.** | Name of reporting person<br>**Perceptive Life Sciences Master Fund, Ltd.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**CAYMAN ISLANDS** | Citizenship or place of organization<br>**CAYMAN ISLANDS** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**88374.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**88374.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**88374.00** | Aggregate amount beneficially owned by each reporting person<br>**88374.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**5.0%** | Percent of class represented by amount in Row (11)<br>**5.0%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**CO** | Type of Reporting Person (See Instructions)<br>**CO** | |

---

| **CUSIP No.** | **55234L204** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Perceptive LS (A), LLC** | Name of reporting person<br>**Perceptive LS (A), LLC** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**CAYMAN ISLANDS** | Citizenship or place of organization<br>**CAYMAN ISLANDS** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**9927.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**9927.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**9927.00** | Aggregate amount beneficially owned by each reporting person<br>**9927.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**0.6%** | Percent of class represented by amount in Row (11)<br>**0.6%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**CO** | Type of Reporting Person (See Instructions)<br>**CO** | |

---

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, $0.001 par value

**(b) Name of Issuer:**
Lyra Therapeutics, Inc.

**(c) Address of Issuer's Principal Executive Offices:**
480 Arsenal Way, Watertown, MA, 02472

**Item 5. Interest in Securities of the Issuer**

**(a)**
Items 5(a)-(c) of the Schedule 13D are amended and supplemented as follows:

The information set forth in rows 11 and 13 of the cover pages to this Schedule 13D is incorporated by reference. The percentage set forth in row 13 is based on 1,774,882 outstanding shares of Common Stock as of November 7, 2025 as reported by the Issuer in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 12, 2025.

**(b)**
The information set forth in rows 7 through 10 of the cover pages to this Schedule 13D is incorporated by reference.

**(c)**
Except as set forth on Schedule A, no Reporting Person has effected any transaction in shares of Common Stock since the filing of Amendment No. 8 to the Schedule 13D, filed with the Securities and Exchange Commission on November 13, 2025.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Perceptive Advisors LLC

**Signature:** /s/ Joseph Edelman

**Name/Title:** Joseph Edelman, Managing Member

**Date:** 11/18/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Joseph Edelman

**Signature:** /s/ Joseph Edelman

**Name/Title:** Joseph Edelman

**Date:** 11/18/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Perceptive Life Sciences Master Fund, Ltd.

**Signature:** /s/ Joseph Edelman

**Name/Title:** Joseph Edelman, Managing Member

**Date:** 11/18/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Perceptive LS (A), LLC

**Signature:** Perceptive LS GP, LLC

**Name/Title:** Joseph Edelman,  Member

**Date:** 11/18/2025